Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mycobacteria, Atypical Clear all
Completed Phase 4 Interventional

Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)

NCT00600769
View directory record Official record
Conditions
Nontuberculous Mycobacteria, Mycobacterium Avium Complex
Interventions
Clarithromycin
Drug
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2017
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 22, 2026, 2:49 PM EDT
Completed No phase listed Observational

A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida

NCT02198079
View directory record Official record
Conditions
Cystic Fibrosis, Pediatrics
Interventions
Sputum
Biological
Lead sponsor
University of Miami
Other
Eligibility
Up to 18 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Jul 22, 2026, 2:49 PM EDT
Completed No phase listed Observational

Cough-Generated Aerosols of NTM in Cystic Fibrosis

NCT01815866
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
CF with culturable NTM
Procedure
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 22, 2026, 2:49 PM EDT
Terminated Phase 3 Interventional

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions
Clofazimine Inhalation Suspension, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 22, 2026, 2:49 PM EDT
Recruiting Phase 4 Interventional

Hypertonic Saline for MAC

NCT04921943
View directory record Official record
Conditions
Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection
Interventions
Hypertonic saline, Azithromycin, Ethambutol, Rifampin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jul 22, 2026, 2:49 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy

NCT00002085
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections, Tuberculosis, Mycobacterium Infection
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Groton, Connecticut • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

NCT04922554
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
Interventions
Omadacycline Oral Tablet, Placebo
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Stanford, California • Washington D.C., District of Columbia • Clearwater, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jul 22, 2026, 2:49 PM EDT
Completed Phase 2Phase 3 Interventional

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

NCT03672630
View directory record Official record
Conditions
Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection
Interventions
Azithromycin, Ethambutol, Rifampin
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
25
States / cities
Loma Linda, California • San Diego, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 22, 2026, 2:49 PM EDT
Recruiting No phase listed Observational

Evaluation Of The Lung Microbiome In NTM Bronchiectasis

NCT02779478
View directory record Official record
Conditions
Nontuberculous Mycobacteria, Bronchiectasis
Interventions
Bronchoscopy
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 22, 2026, 2:49 PM EDT
Recruiting No phase listed Observational

Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)

NCT06155747
View directory record Official record
Conditions
Nontuberculous Mycobacterial Pulmonary Infection, Outbreak Investigation, Healthcare Associated Infection, Mycobacterium Infections
Interventions
Epidemiologic investigation
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Month to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 22, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection

NCT03748992
View directory record Official record
Conditions
Nontuberculous Mycobacterium Infection
Interventions
gNO
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Portland, Oregon • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Jul 22, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

NCT01315236
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
Liposomal amikacin for inhalation (LAI), placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Jul 22, 2026, 2:49 PM EDT
Enrolling by invitation No phase listed Observational

Prospective Healthcare-Associated Links in Transmission of Nontuberculous Mycobacteria

NCT05686837
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterial Pulmonary Infection
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Month to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Denver, Colorado • Baltimore, Maryland • Austin, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 22, 2026, 2:49 PM EDT
Completed No phase listed Observational

Healthcare-associated Links in Transmission of Nontuberculous Mycobacteria in Cystic Fibrosis

NCT04024423
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterium Infection
Interventions
Epidemiologic investigation
Other
Lead sponsor
National Jewish Health
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Jul 22, 2026, 2:49 PM EDT
Not listed No phase listed Observational

PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis

NCT02073409
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
6 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Jul 22, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

NCT04884308
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
Interventions
BCG TICE Vaccine
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 22, 2026, 2:49 PM EDT
Not listed No phase listed Observational

PATIENCE Trial: Prospective Algorithm for Treatment of NTM in Cystic Fibrosis

NCT02419989
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
6 Years to 99 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Jul 22, 2026, 2:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

NCT02372383
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ethambutol, Rifampin, Azithromycin, Pancrelipase
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
16 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Jul 22, 2026, 2:49 PM EDT
Completed Phase 1 Interventional

Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections

NCT00001911
View directory record Official record
Conditions
Atypical Mycobacterium Infection
Interventions
Interleukin-12
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 2:49 PM EDT
Completed Phase 2 Interventional

Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

NCT03038178
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical
Interventions
LAI plus multi-drug regimen
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Portland, Oregon • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Jul 22, 2026, 2:49 PM EDT
Completed Phase 1 Interventional

Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV

NCT00002104
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections, Tuberculosis, Mycobacterium Infection
Interventions
Thalidomide
Drug
Lead sponsor
Aaron Diamond AIDS Research Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 2:49 PM EDT
Recruiting Phase 2 Interventional

Epetraborole in Patients With Mycobacterium Abscessus Lung Disease

NCT07301320
View directory record Official record
Conditions
Mycobacterium Abscessus Infection
Interventions
Epetraborole, Placebo
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 2:49 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

NCT05327803
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease
Interventions
Epetraborole, Placebo
Drug
Lead sponsor
AN2 Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 2:49 PM EDT
Recruiting Phase 2 Interventional

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

NCT05730283
View directory record Official record
Conditions
Ototoxicity, Drug-Induced
Interventions
ORC-13661, Placebo
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 2:49 PM EDT